Search Results - "Lundblad, Mia"
-
1
A novel quinoline with airway relaxant effects and anti-inflammatory properties
Published in Respiratory research (30-03-2024)“…In chronic pulmonary diseases characterized by inflammation and airway obstruction, such as asthma and COPD, there are unmet needs for improved treatment…”
Get full text
Journal Article -
2
First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis
Published in PloS one (07-08-2015)“…The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the…”
Get full text
Journal Article -
3
Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes
Published in Biochemical and biophysical research communications (25-02-2005)“…Arachidonic acid is oxidized by cytochromes P450 2C (CYP2C) to epoxyeicosatrienoic acids (EETs), possessing vasoactive properties, with 11,12-EET as the…”
Get full text
Journal Article -
4
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
Published in European journal of clinical pharmacology (01-08-2005)“…The purpose of the study was to study the distribution of poor and extensive metabolizers of CYP2C19 and CYP2D6 and to genotype for CYP2C8 and CYP2C9 among 312…”
Get full text
Journal Article -
5
Clinical Pharmacokinetics of the Anti-Interleukin-20 Monoclonal Antibody NNC0109-0012 in Healthy Volunteers and Patients with Psoriasis or Rheumatoid Arthritis
Published in Advances in therapy (01-03-2015)“…Introduction NNC0109-0012, a novel human monoclonal antibody that binds to and neutralizes the activity of interleukin–20, was investigated as a potential…”
Get full text
Journal Article -
6
Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency
Published in Blood (15-11-2013)“…Three trials, F13CD-1725, F13CD-3760 and F13CD-3720 have investigated the pharmacokinetics (PK) of recombinant FXIII (rFXIII), given at a dose of 35 IU/kg once…”
Get full text
Journal Article -
7
Reply
Published in Clinical pharmacology and therapeutics (01-09-2006)Get full text
Journal Article -
8
Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
Published in Omics (Larchmont, N.Y.) (01-06-2015)“…Global personalized medicine demands the characterization of person-to-person and between-population differences in drug pharmacokinetics and pharmacodynamics…”
Get more information
Journal Article -
9
First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis: e0134703
Published in PloS one (01-08-2015)“…Background The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary…”
Get full text
Journal Article -
10
Accumulation of celecoxib with a 7‐fold higher drug exposure in individuals homozygous for CYP2C93
Published in Clinical pharmacology and therapeutics (01-03-2006)Get full text
Journal Article -
11
Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C93 allele? Reply
Published in Clinical pharmacology and therapeutics (2006)Get full text
Journal Article -
12
Interindividual Variation in Drug Metabolism with Focus on Polymorphic Cytochrome P450 2C9
Published 01-01-2005“…Cytochromes P450 (CYP) are enzymes, mainly catalysing the oxidation of xenobiotics, in order to facilitate their excretion from the body. CYP2C9 is a…”
Get full text
Dissertation